Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapastinel Relapse Prevention in MDD
NCT02951988Phase 3Completed
- Sponsor
- Allergan
- Start
- Nov 2016
- Primary completion
- Feb 2019
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rapastinel in major depressive disorder (MDD) (3 arms), sponsored by Allergan. Primary endpoint: Time to First Relapse During the First 52 Weeks of the Double-Blind Treatment Period. Started Nov 2016; status: completed.
02
Drugs
rapastinel
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02951988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02951988.